A comprehensive Crohn’s disease assessment tool

stride
calm

A comprehensive Crohn’s disease assessment tool

In Crohn’s disease (CD) patient management, endoscopic healing is known to be an objective measure of therapeutic response.3 This is likely due to the fact that, in multiple clinical trials, endoscopic healing is a therapeutic goal that has been associated with improved long-term outcomes in CD patients3-6

However, current assessment methods can make it challenging to:

  • Noninvasively evaluate the endoscopic disease activity of your adult CD patients7,8
  • Assess active disease in difficult-to-reach locations, including the ileum3,6,8
  • Obtain objective results for individual patients7
  • Regularly monitor patient response to therapy7
 

Measure and monitor the endoscopic disease activity of your adult CD patients with 1 simple serum test

The PROMETHEUS® Monitr™ Crohn’s Disease Test is a laboratory-developed test that provides critical information to aid in:


Establishing a baseline measurement of disease activity at initial presentation

Tracking and assessing disease activity and response to therapeutic management

Optimizing treatment management decisions

Evaluating if treatment changes may be appropriate

Counseling patients about therapeutic management goals

Reinforcing importance of patient compliance to continue therapy

A powerful monitoring tool for CD patients.

Easy to order: Monitr™ Test Requisition Form. For assistance ordering, contact your local Prometheus Biosciences representative, or Client Services toll-free in the US at 888-423-5227 (Monday through Friday from 6 AM to 4:30 PM PT).

References

References:
  1. 1. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324-1338.

  2. 2. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779-2789

  3. 3.De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn’s disease: a systematic review. Inflamm Bowel Dis. 2013;19(2):429-444.

  4. 4.Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412-422.

  5. 5.Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142(5):1102-1111.e2.

  6. 6.Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther. 2016;43(3):317-333.

  7. 7.Freeman HJ. Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol. 2010;16(1):15-20.

  8. 8.Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis. 2014;8(12):1582-1597.